U.S. health regulators have approved another antiviral pill against COVID-19, by Merck another easy-to-use drug to combat the rising tide of Omicron variant.
Trial data shows the oral pill by Pfizer is 90 percent effective in preventing deaths and hospitalisations in high-risk patients